Cargando…
Bioequivalence of levamlodipine besylate tablets in healthy Chinese subjects: a single-dose and two-period crossover randomized study
BACKGROUND: Levamlodipine, a calcium channel blocker, has been show act as a cardiovascular drug. To compare the pharmacokinetic parameters between levamlodipine (test formulation) at a single dose of 5 mg and amlodipine (reference formulation) at a single dose of 10 mg, the bioequivalence study was...
Autores principales: | Li, Xin, Wang, Chenjing, Li, Ting, Liu, Yanping, Liu, Shuqin, Tao, Ye, Ma, Yaping, Gao, Xiaomeng, Cao, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678077/ https://www.ncbi.nlm.nih.gov/pubmed/33213527 http://dx.doi.org/10.1186/s40360-020-00459-6 |
Ejemplares similares
-
Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia
por: Yao, Kai-Xin, et al.
Publicado: (2019) -
Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects
por: Sun, Feifei, et al.
Publicado: (2023) -
Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects
por: Li, Ting, et al.
Publicado: (2022) -
Clinical assessment of levamlodipine besylate combination therapy for essential hypertension: A protocol for systematic review and meta-analysis
por: Dai, Guo-Yao, et al.
Publicado: (2022) -
Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects
por: Lee, Soo-Yun, et al.
Publicado: (2015)